Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:08 AM
Ignite Modification Date:
2025-12-25 @ 2:08 AM
NCT ID:
NCT00690560
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Histologically confirmed large B-cell lymphoma
* Stage I, II, III, or IV disease
* Bone marrow or lymph node involvement by small cell lymphoma allowed
* No serious, progressive pathology (at investigator's discretion)
* CD20-positive disease
* Measurable disease
* No prior indolent lymphoma, treated or not
* No meningeal or CNS lymphoma
PATIENT CHARACTERISTICS:
* International prognostic index \< 2 (adjusted for age)
* Life expectancy \> 3 months
* ALT and AST ≤ 2.5 times upper limit of normal
* Bilirubin ≤ 30 mmol/L
* Creatinine ≤ 150 μmol/L
* HIV, hepatitis B virus, and hepatitis C virus negative (unless after vaccine)
* No contraindication to chemotherapy or immunotherapy
* No cancer in the past 5 years except basal cell skin cancer or carcinoma in situ of the cervix
* No contraindication to a venous catheter
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
* At least 30 days since prior and no other concurrent investigational treatment
* No prior therapy
* No concurrent participation in another clinical study
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
65 Years
Maximum Age:
80 Years
Study:
NCT00690560
Study Brief:
Protocol Section:
NCT00690560